PaxMedica

We are an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells. Our primary focus is currently on the development and testing of our lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. We are also focused on the treatment of Human African Trypanosomiasis (or HAT), where we are seeking to leverage suramin’s historical use in this indication, and data that we have exclusively licensed directly from certain academic or international government institutions to potentially accelerate PAX-101’s development in the U.S.